(Other OTC:INVU),(OTC US:INVU),(OTC US:INVUP),(Other OTC:INVUP), HAVERFORD, PA, March 06, 2025 (GLOBE NEWSWIRE) — Investview, Inc. (OTCQB: INVU), operates a diversified financial technology services company offering multiple business units across key sectors. These include a financial education division offering tools, content, and research through a global network of independent distributors; a manufacturing division focused on proprietary […]

(NASDAQ:AVDX), CHARLOTTE, N.C., March 06, 2025 (GLOBE NEWSWIRE) — AvidXchange Holdings, Inc. (Nasdaq: AVDX), a leading provider of accounts payable (AP) automation software and payment solutions for middle market businesses and their suppliers, today announced that members of the management team will participate in the Wolfe FinTech Forum 2025 in New York, NY on Wednesday,

(NASDAQ:ACHV), SEATTLE and VANCOUVER, British Columbia, March 06, 2025 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced it will report its fourth quarter and year-end 2024 financial results and

(TSX-V:SCAN),(Frankfurt:LD2A),(OTC US:LDDFF),(OTCQB:LDDFF),(Frankfurt:E30), WILMINGTON, Mass., March 06, 2025 (GLOBE NEWSWIRE) — Liberty Defense Holdings Ltd. (“Liberty” or the “Company“) (TSXV: SCAN, OTCQB: LDDFF, FSE: E30), a leading technology provider of AI-based next generation detection solutions for concealed weapons and threats, is pleased to announce it has started their SAFETY Act (Support Anti-Terrorism by Fostering Effective Technologies

(NASDAQ:LSTA), BASKING RIDGE, N.J., March 06, 2025 (GLOBE NEWSWIRE) — Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that David J. Mazzo, Ph.D., President and Chief Executive Officer of Lisata, will present a corporate

(NASDAQ:DYAI), JUPITER, Fla., March 06, 2025 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as non-pharmaceutical applications including food, non-food and industrial applications today announced its

(Other OTC:WNLV),(OTC US:WNLV), RENO, NV, March 06, 2025 (GLOBE NEWSWIRE) — Winvest Group Limited (OTCQB: WNLV) (“Winvest”), an investment holding company with diverse media, entertainment, and technology portfolios, is pleased to announce that its subsidiary IQI Media Inc. will be offering beta demos of Launchrr, its proprietary SaaS solution for the film and television industry,

(NASDAQ:CLNN), SALT LAKE CITY, March 06, 2025 (GLOBE NEWSWIRE) — Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will participate

(Euronext Amsterdam:INGA),(Brussels:INGA), ING publishes 2024 Annual Report on Form 20-F ING filed today its Annual Report on Form 20-F for the year ended 31 December 2024 with the United States Securities and Exchange Commission (SEC). The 2024Form 20-F will be available on the ING website and can be downloaded from the SEC website (sec.gov) today.

(NASDAQ:BDRX), March 6, 2025 Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP Biodexa is finalizing plans to initiate an international Phase 3 registrational study of eRapa in Familial Adenomatous Polyposis (FAP) next quarter Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq: BDRX),